Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis..

诺华公司今天宣布，已成功完成对Regulus Therapeutics Inc.（“Regulus”）的收购。随着收购的完成，Regulus的普通股，每股面值0.001美元（“股份”），已在纳斯达克股票市场有限责任公司停止交易，Regulus现在是诺华的间接全资子公司。

“We are pleased to complete this transaction and take the next step in advancing clinical development for a potential first-in-class medicine that can help treat patients suffering from ADPKD (autosomal dominant polycystic kidney disease), the most common genetic cause of renal failure worldwide1,” said Shreeram Aradhye, President, Development and Chief Medical Officer, Novartis.

“我们很高兴完成这一交易，并在推进潜在的首创药物的临床开发方面迈出下一步，这种药物可以帮助治疗 ADPKD（常染色体显性多囊肾病）患者，ADPKD 是全球肾功能衰竭最常见的遗传原因，”诺华公司开发部总裁兼首席医学官 Shreeram Aradhye 表示。

“We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.”.

“我们很高兴欢迎Regulus的才华横溢的团队加入诺华，因为我们继续在肾脏疾病领域未满足医疗需求的高需求中建立我们的研发管线。”

Farabursen is an investigational next-generation oligonucleotide targeting miR-17 with preferential kidney exposure, aiming to reduce the growth of cysts and kidney size, as well as delay progression of disease severity in ADPKD. In March 2025, Regulus announced the successful completion of its Phase 1b multiple-ascending dose clinical trial for farabursen.

Farabursen 是一种研究中的新一代寡核苷酸，靶向 miR-17，具有优先的肾脏暴露特性，旨在减少囊肿生长和肾脏体积，并延缓 ADPKD 疾病严重程度的进展。2025 年 3 月，Regulus 宣布成功完成了 Farabursen 的 1b 期多剂量递增临床试验。

The Phase 1b trial data showed promising clinical efficacy and safety, including consistent impact on urinary polycystin (PC), a biomarker of mechanistic response, and height-adjusted total kidney volume (htTKV), an established meaningful clinical measure of disease progression..

1b期试验数据显示出令人鼓舞的临床疗效和安全性，包括对尿多囊蛋白（PC）这一机制反应的生物标志物的一致影响，以及身高调整后的总肾体积（htTKV）这一已确立的、有意义的疾病进展临床指标。

Novartis’ previously announced tender offer to acquire all of the outstanding Shares in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a “CVR”) per Share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone, expired at one minute past 11:59 p.m., New York City Time, on June 24, 2025.

诺华公司此前宣布的要约收购所有已发行股份的提议，以每股7.00美元现金（视任何适用的预扣税而定，且不计利息）加上每股一份或有增值权（“CVR”），该权利代表在达成监管里程碑时获得一笔7.00美元现金的或有支付权利（视任何适用的预扣税而定，且不计利息），已于2025年6月24日纽约时间晚上11点59分过1分钟到期。

Approximately 56,374,397 Shares were validly tendered, and not validly withdrawn from the tender offer, representing approximately 74.49% of the issued and outstanding Shares. In accordance with the terms of the tender offer, all Shares that were validly tendered and not validly withdrawn have been accepted for payment and paid for..

大约有56,374,397股有效提交，并且没有从要约收购中有效撤回，占已发行和流通股的约74.49%。根据要约收购的条款，所有有效提交且未有效撤回的股份已被接受支付并已完成付款。

Following completion of the tender offer, Novartis completed the acquisition of Regulus through the merger of its indirect wholly owned subsidiary, Redwood Merger Sub Inc., with and into Regulus, without a vote of Regulus’ stockholders pursuant to Section 251(h) of the General Corporation Law of the State of Delaware.

在要约收购完成后，诺华通过其间接全资子公司Redwood Merger Sub Inc.与Regulus的合并完成了对Regulus的收购，且根据特拉华州普通公司法第251(h)条的规定，无需Regulus股东投票。

As a result of the merger, each Share issued and outstanding and not tendered in the tender offer was canceled and extinguished and automatically converted into the right to receive the same consideration (including the CVR) per Share payable in the tender offer..

作为合并的结果，每一份已发行且未在要约收购中提交的股份被取消和注销，并自动转换为获得相同对价（包括CVR）的权利，该对价按要约收购中每股应付的金额支付。

About Novartis

关于诺华

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

诺华是一家创新药物公司。每一天，我们都在努力重新构想药物，以改善和延长人们的生命，使患者、医疗专业人员和社会能够在面对严重疾病时获得力量。我们的药物惠及全球近3亿人。